SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

14 Feb 2023 Evaluate
The sales is pegged at Rs. 1051.40 millions for the December 2022 quarter. The mentioned figure indicates decline with the sales recorded at Rs. 1170.00 millions during the year-ago period.The company suffered a huge decline of -75.99% to Rs. 95.17  millions from Rs. 396.39 millions  of corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 166.07 millions from 438.17 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 1051.40 1170.00 -10.14 3186.67 3418.00 -6.77 5300.49 3912.45 35.48
Other Income 25.64 54.42 -52.88 75.26 107.02 -29.68 75.77 49.77 52.24
PBIDT 166.07 438.17 -62.10 1043.57 1583.13 -34.08 2215.62 1781.51 24.37
Interest 10.14 11.49 -11.75 253.50 190.10 33.35 41.98 40.80 2.89
PBDT 155.93 426.68 -63.46 790.07 1393.03 -43.28 2173.64 1740.71 24.87
Depreciation 29.50 25.99 13.51 88.08 75.39 16.83 101.18 67.61 49.65
PBT 126.43 400.69 -68.45 701.99 1317.64 -46.72 2072.46 1673.10 23.87
TAX 31.26 4.30 626.98 185.70 261.65 -29.03 554.35 437.16 26.81
Deferred Tax 7.05 -119.86 -105.88 10.96 -75.79 -114.46 32.46 6.94 367.72
PAT 95.17 396.39 -75.99 516.29 1055.99 -51.11 1518.11 1235.94 22.83
Equity 160.97 160.96 0.01 160.97 160.96 0.01 160.97 146.37 9.97
PBIDTM(%) 15.80 37.45 -57.82 32.75 46.32 -29.30 41.80 45.53 -8.20

Supriya Lifescience Share Price

636.90 -1.05 (-0.16%)
13-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1652.00
Dr. Reddys Lab 1235.20
Cipla 1211.30
Zydus Lifesciences 923.10
Lupin 2312.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×